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Purpose: The purpose of this study was to determine the outcome of nonoperative management (NOM) of asymptomatic
high-grade (80% to 99%) carotid stenosis.
Methods: From April 1994 to December 2000, asymptomatic high-grade (80% to 99%) carotid stenosis was identified in
196 carotid arteries in 180 male veterans. Of the original number identified, 137 carotid endarterectomies (CEs) were
performed in 123 patients (OP group) and 59 carotid arteries in 57 patients were managed nonoperatively (NOM
group.) The NOM group was further subdivided into those patients who refused care (NOM-R group; n  21; 36.8%)
versus those who were not offered CE on the basis of comorbid conditions (NOM-C group; n  36; 63.2%). Clinical
follow-up was obtained to determine rates of neurologic events, patient survival, and progression to occlusion.
Results: During the follow-up period, a total of 13 ipsilateral neurologic events occurred: two amaurosis fugax (15.4%),
two transient ischemic attacks (15.4%), and nine strokes (69.2%). The NOM-R group had a significantly lower ipsilateral
neurologic event-free rate when compared with the OP group at both 18 months (81%  9.8% versus 96%  1.8%; P <
.02) and 2 years (81%  10.6% versus 95%  2.1%; P < .04.) However, the NOM-C group and the OP group had no
significant difference in their ipsilateral neurologic event-free rate out to 3 years (96%  6.8% versus 95%  2.7%). As
would be expected, the NOM-C group had a much lower patient survival rate when compared with either the OP group
(59% 9.2% versus 84% 3.6% at 2 years; P < .002) or the NOM-R group (59% 9.2% versus 100% at 2 years; p < .0001).
The cumulative patency rate of carotid arteries in the NOM group was 86%  7.6% at 3 years. Progression to occlusion was
associated with a neurologic event in two of five occurrences. No carotid artery progressed to occlusion in the OP froup.
Conclusion: Although CE is the preferred treatment for asymptomatic high-grade carotid stenosis, NOM is an acceptable
alternative in selected patients at high risk with diminished life expectancy. (J Vasc Surg 2002;36:663-7.)
Carotid endarterectomy (CE) has been established as a
safe, durable, and effective method to treat symptomatic
and asymptomatic carotid artery stenosis.1,2 Nevertheless,
the North American Symptomatic Carotid Endarterectomy
Trial (NASCET) and the Asymptomatic Carotid Artery
Stenosis (ACAS) trial had selective inclusion and exclusion
criteria that may not be applicable to a broader patient
population. This has led some groups to recommend ca-
rotid artery angioplasty/stenting (CAS) as a possible alter-
native to CE in selected patients. CAS has recently been
recommended as a treatment alternative for asymptomatic
carotid stenosis in patients who are at high risk for surgery
on the assumption that it will result in lowered neurologic
events and procedural complications.3,4 In contrast, at our
institution, we have taken a conservative approach of non-
operative management (NOM) in patients at high risk with
asymptomatic high-grade (80% to 99%) carotid stenosis.
The objective of this retrospective study was to determine
the outcome of this NOM of asymptomatic high-grade
carotid stenosis in patients at high risk and compare it with
operative management and patients who refuse surgery.
PATIENTS AND METHODS
Patient selection and follow-up. All veterans seen at
the noninvasive vascular laboratory at Hines Veterans Af-
fairs Administration Hospital in Hines, Ill, with a high-
grade (80% to 99%) internal carotid artery stenosis as de-
fined by a end-diastolic velocity of more than 140 cm/s
from April 1994 to December 2000 were included in the
study. Cerebrovascular studies were performed with ATL
Ultramark 9 high definition imaging (HDI, Advanced
Technology Laboratories, Bothell, Wash) by two experi-
enced vascular technologists, one of whom is certified. All
studies were reviewed by the vascular surgery attending
physicians. Quality assurance assessments have verified the
accuracy of our vascular laboratory. For 167 vessels exam-
ined during a 3-year period with both color-flow scanning
and arteriography, the sensitivity, specificity, positive pre-
dictive values, and negative predictive values were 99%,
96.8%, 98.1%, and 98.4%, respectively. The overall accu-
racy was 98.2%. Patients with recurrent carotid stenosis
were excluded from the study. Both patients for NOM and
operative management were followed with duplex exami-
nations and clinical evaluation every 6 months. Patients lost
to follow-up in the noninvasive vascular laboratory had
follow-up obtained through chart review and telephone
interviews. Information was obtained on neurologic events,
patient survival, progression of carotid disease, and rates of
progression to occlusion. All patient chart data were col-
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lected retrospectively, with the exception of perioperative
neurologic events, which were collected prospectively.
Statistical analysis. Patient survival rates, rates of
progression of disease and progression to occlusion, and
ipsilateral neurologic event-free rates were calculated with
Kaplan-Meier life tables in accordance with Society for
Vascular Surgery recommended standards.5,6 Patients were
withdrawn from study after death, end of study interval,
loss to follow-up, and final neurologic event and in the case
of NOM after conversion to surgery. Patients withdrawn
from the NOM group because of conversion to surgery
were not followed as operative patients. Statistical signifi-
cance was determined with 2 test and Fisher exact test as
appropriate with Sigmastat 2.0 software (Jandel Corpora-
tion, San Rafael, Calif). Significance was set at a P value of
less than .05.
RESULTS
From April 1994 to December 2000, asymptomatic
high-grade carotid stenosis was identified in 196 carotid
arteries in 180 male veterans. Of the original number
identified, 137 CEs were performed in 123 patients (OP
group) and 59 carotid arteries in 57 patients were managed
nonoperatively (NOM group.) The NOM group was fur-
ther subdivided into those patients who refused care
(NOM-R group; n 21; 36.8%) versus those who were not
offered CE on the basis of comorbid conditions (NOM-C
group; n  36; 63.2%). The average age of patients was
71  6.65 years. The median follow-up period was 34 
20.7 months. Patient risk factors in the NOM group in-
cluded hypertension (63.2%), coronary artery disease
(64.9%), diabetes mellitus (31.6%), tobacco abuse (54.4%),
hyperlipidemia (17.5%), and chronic obstructive pulmo-
nary disease (35.1%). Reasons for patients in the NOM-C
group to be managed without CE included frail general
medical condition in 14 patients (38.9%), advanced malig-
nant disease in 10 patients (27.8%), severe cardiac disease in
six patients (16.7%), dementia in four patients (11.1%), and
inoperable lesion/frail medical condition in two patients
(5.5%). Frail general medical condition refers to patients
who did not specifically have one defining reason to have
NOM recommended, nevertheless the clinical decision of
the evaluating surgeon in these patients was that NOM
would be the best option because of overall poor medical
condition. No neurologic events occurred in those
NOM-C group patients denied CE on the basis of ad-
vanced malignant disease, severe cardiac disease, dementia,
or inoperable lesion/frail medical condition.
During the follow-up period, 13 total ipsilateral neu-
rologic events occurred; two amaurosis fugax (AF; 15.4%),
two transient ischemic attacks (TIAs; 15.4%), and nine
strokes (69.2%). Table I summarizes all neurologic events
in all groups for the entire study period. The NOM-R
group had a significantly lower ipsilateral neurologic event-
free rate when compared with the OP group at both 18
months (81%  9.8% versus 96%  1.8%; P  .02) and 2
years (81%  10.6% versus 95%  2.1%; P  .04). How-
ever, the NOM-C group and the OP group had no signif-
icant difference in their ipsilateral neurologic event-free rate
out to 3 years (96%  6.8% versus 95%  2.7%; Figs 1 and
2; Table II). Major stroke occurred in two patients in the
OP group (1.4%). One was a perioperative stroke, and the
other occurred 20 months after surgery. The remainder of
neurologic events in the OP group included four mild
strokes with full recovery. Minor stroke was defined as a
neurologic deficit lasting less than 7 days and with minimal
disability. Major stroke was defined as a neurologic deficit
lasting longer than 7 days and with significant disability/
impairment.
Crossover to surgery did not occur in the NOM-C
group. During the follow-up period, nine patients in the
NOM-R group crossed over to surgery. Five of these
changed their mind with regard to surgery. The remaining
four patients had TIA/AF develop, which persuaded them
to undergo surgery. One of these patients had an intraop-
erative major stroke, and this was included as a neurologic
event in the NOM-R group. The mean time to crossover
was 15.8  3.6 months after assignment to the NOM-R
group (Table III).
As would be expected, the NOM-C group had a much
lower patient survival rate when compared with either the
OP group (59%  9.2% versus 84%  3.6% at 2 years; P 
.002) or the NOM-R group (59% 9.2% versus 100% at 2
years; P  .0001; Fig 3; Tables IV and V). The cumulative
patency rate of carotid arteries in the NOM group was 86%
 7.6% at 3 years. Progression to occlusion was associated
with a neurologic event in two of five vessels. Both of these
Fig 1. Ipsilateral neurologic event-free rates of OP group versus
NOM-R group (P  .04).
Table I. Total number of ipsilateral neurologic events in
each patient category
TIA/AF
n (%)
Minor stroke
n (%)
Major stroke
n (%)
OP group 0 4 (2.9) 2 (1.4)
NOM-C group 0 0 1 (2.6)
NOM-R group 4 (19.0) 0 2 (9.5)
Number in parentheses is percentage of total number of carotids
in that treatment category.
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events were strokes. One each occurred in the NOM-R and
NOM-C groups. No carotid artery progressed to occlusion
in the OP group.
DISCUSSION
CE is a safe, effective, and durable procedure for both
symptomatic and asymptomatic carotid lesions.1,2 For
asymptomatic carotid stenosis greater than 60%, the ACAS
trial was able to show a 53% relative risk reduction in death
and ipsilateral stroke at 5 years in the operated group. These
results have caused an increase in the number of CE proce-
dures being performed; however, the selective inclusion
criteria of the ACAS trial may make application of its results
to a broader patient population difficult. Specifically, pa-
tients at surgical high risk with shortened life expectancy
may not be able to benefit from the long-term stroke
prevention of CE. Several studies examining certain pa-
tients at high risk or trial ineligible who underwent CE have
shown acceptable outcomes. O’Hara et al7 studied the
outcome of CE on 167 octogenarians at the Cleveland
Clinic Foundation, including 100 procedures on asymp-
tomatic patients. No difference was found compared with
younger patients in early postoperative stroke rate (1.6%
versus 2.2%) or mortality rate (1.8% versus 1.1%).7 Jordan
et al8 reviewed CE in 98 patients considered at high risk on
the basis of severe cardiac dysfunction (n 30), combined
cardiac and carotid revascularization (n  14), severe pul-
monary dysfunction (n  8), contralateral carotid occlu-
sion (n  31), prior CE (n  25), and inaccessible lesion
(n  4). In comparison of this group with 317 patients at
lower risk, the high-risk group did not have a significantly
different ipsilateral stroke rate (2.0% versus 1.9%).8 Lepore
et al9 reviewed 169 patients who were trial ineligible for
either NASCET or ACAS. This group overall had six
perioperative strokes. A combined perioperative major
stroke and death rate of 1.7% was not significantly different
from patients who were trial eligible.9 Although these
results support the use of CE in broader patient populations
than the original NASCET and ACAS trials allowed, a
certain selection bias can be assumed because all patients
were deemed at acceptable risk for surgery.
Our study examined the outcome of NOM in patients
who were specifically considered at prohibitive risk for
surgery or who refused surgery. On the basis of a previous
study, our policy has been to recommend surgery for
duplex scan–diagnosed carotid artery stenosis of 80% to
99% in asymptomatic patients.10 We have adopted a policy
of following all moderate (50% to 79%) carotid lesions and
that group of patients with asymptomatic high-grade ste-
nosis judged to be at unacceptable operative risk.
In comparison of this high-risk NOM-C group with
the group undergoing surgery, no difference was found in
ipsilateral neurologic event-free rates. This is probably re-
lated to the high mortality rate (41% 10% patient survival
at 3 years) in the NOM-C group. In other words, it seems
the NOM-C group patients were more likely to die of a
noncerebrovascular event than to have an ipsilateral neuro-
logic event develop from their asymptomatic carotid lesion.
Indeed, in long-term follow-up, only one of 38 carotids
(2.6%) resulted in a neurologic event. In contrast, those
patients who refused surgery against recommendations had
a lower ipsilateral neurologic event-free rate than patients
who underwent surgery. Furthermore, nine of these pa-
tients converted to surgery, four after the development of
TIA/AF. Major stroke occurred in 9.5% of the NOM-R
group versus only 1.4% of the OP group during all follow-
up. Also, patient suvival in the NOM-R group was more
consistent with the OP group and significantly better than
the NOM-C group. Because of the variety of comorbidities
that resulted in NOM, it is difficult to give specific recom-
Fig 2. Ipsilateral neurologic event-free rates of OP group versus
NOM-C group.
Table II. Ipsilateral neurologic event-free rates for NOM-C group
Interval
(mo)
No. of
carotids at
risk
Ipsilateral
neurologic
events Duration
Loss to
follow-up
Nonstroke
death
Interval
ipsilateral
neurologic
event-free rate
Cumulative
ipsilateral
neurologic
event-free rate
Standard
error
0-1 38 0 0 0 0 1.0 100% 0
1-6 38 0 0 0 2 1.0 100% 0
6-12 36 0 1 0 8 1.0 100% 0
12-18 27 1 1 2 4 0.96 100% 0
18-24 19 0 0 1 3 1.0 96% 4.4%
24-36 15 0 1 1 5 1.0 96% 5.0%
36-48 8 0 3 0 2 1.0 96% 6.8%
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mendations for whom NOM would be suited. Neverthe-
less, NOM would appear to be an acceptable and perhaps
preferable alternative for high-grade asymptomatic carotid
lesions in patients at high risk with diminished life expect-
ancy.
No difference was noted between the groups when
stoke alone was analyzed as an endpoint. Given the size of
our study, this is not surprising. In this situation, combined
neurologic events, including TIA and AF, may provide
more useful data as, for example, was done in the Veterans
Affairs Study of asymptomatic carotid stenosis.11 We agree
with the following statement made in this study regarding
the use of TIA and stroke as an endpoint, “Including
transient ischemic attacks in the analysis of neurologic
outcomes is justified by their importance as indicators or
predictors of stroke. Differentiating a transient ischemic
attack from a stroke causing minimal disability may require
making an unnecessarily rigid distinction in view of the
similarity of their clinical definitions, the subsequent risk of
stroke after transient events, and the acknowledged inci-
dence (30-40%) of abnormal computed tomography and
magnetic resonance scans in patients with clinical evidence
of a transient ischemic attack alone.”11 The use of TIA and
AF as endpoints in our study is particularly relevant in
evaluation of the NOM groups. Those patients with TIAs
in the NOM-R group all converted to surgery after becom-
ing symptomatic. Exclusion of these TIAs in the evaluation
of endpoints would give a misleading neurologic event rate
in this group.
Our results have implications with regard to the most
appropriate management of asymptomatic carotid stenosis.
Despite equivocal results in many reports, CAS is gaining
wider acceptance among clinicians because of its perceived
minimally invasive nature. Although well-constructed pro-
spective randomized trials are lacking, some evidence sug-
gests CAS should not be performed as of yet in asymptom-
atic carotid stenosis.12,13 Some groups advocate CAS as a
viable option for symptomatic and asymptomatic patients at
high risk who might otherwise be denied intervention.3-4,14
Shawl et al3 studied CAS in a group of patients at “high risk”
with unstable angina, previous ipsilateral CE, contralateral
carotid artery occlusion, and severe comorbid illness. Sixty-six
of 170 patients in this series were asymptomatic. This series
had nine deaths during 19 months of follow-up. The 30-day
incidence rate of stroke and death was 2.9%. During a mean
follow-up period of 19 11 months, three patients (2%) had
asymptomatic restenosis, three patients (2%) had minor
strokes, and no patients had major stroke. Yadav et al4 pro-
spectively evaluated CAS in 107 consecutive patients at “high
risk” with 6 months of follow-up. Fifty-two of these patients
were asymptomatic. In the asymptomatic patients, two minor
procedural strokes (4%) were seen. No strokes occurred dur-
ing the follow-up period, but five patients needed another
intervention during the 6 months.
Although these and other series suggest CAS is feasible
in patients at high risk, for it to be justified, one must first
know that NOM of asymptomatic patients at high risk
results in an unacceptable rate of neurologic events. Fur-
thermore, before advocating any intervention in these pa-
tients, diminished life expectancy should also be consid-
ered. Although this is a retrospective study, and thus its
results must be interpreted with caution, our data do sug-
gest that patients at truly high risk with comorbid disease
that contraindicates surgery can be followed without inter-
vention because the risk of neurologic event is low in these
patients with diminished life expectancy.
We conclude that CE is the preferred treatment for
asymptomatic high-grade carotid stenosis. However,
NOM is an acceptable alternative in selected patients at
high risk with a diminished life expectancy.
Fig 3. Cumulative patient survival rates in OP group versus
NOM-C group (P  .002).
Table III. Ipsilateral neurologic event-free rates for NOM-R group
Interval
(mo)
No. of
carotids
at risk
Ipsilateral
neurologic
events Duration
Crossover
to surgery
Loss to
follow-up
Nonstroke
death
Interval
ipsilateral
neurologic
event-free
rate
Cumulative
ipsilateral
neurologic
event-free
rate
Standard
error
0-1 21 0 0 0 0 0 1.0 100% 0
1-6 21 0 0 0 0 0 1.0 100% 0
6-12 21 0 0 0 0 0 1.0 100% 0
12-18 21 4 1 7 0 0 0.81 100% 0
18-24 13 0 2 0 0 0 1.0 81% 9.8%
24-36 11 1 1 1 1 0 0.91 81% 10.6%
36-48 8 1 3 1 0 0 0.88 73% 13.4%
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Table IV. Patient survival in NOM-C group
Interval
(mo)
No. of
patients
at risk Death Duration
Loss to
follow-up
Interval
survival
rate
Cumulative
survival
rate
Standard
error
0-1 36 0 0 0 1.0 100% 0
1-6 36 2 0 0 0.94 100% 0
6-12 34 7 1 0 0.79 94% 3.9%
12-18 26 2 1 2 0.92 74% 7.4%
18-24 21 3 0 1 0.86 68% 8.4%
24-36 17 5 1 1 0.70 59% 9.2%
36-48 10 2 3 1 0.80 41% 10.0%
Table V. Patient survival in NOM-R group
Interval
(mo)
No. of
patients
at risk Death Duration
Loss to
follow-up
Interval
survival
rate
Cumulative
survival
rate
Standard
error
0-1 21 0 0 0 1.0 100% 0
1-6 21 0 0 0 1.0 100% 0
6-12 21 0 0 0 1.0 100% 0
12-18 21 0 1 0 1.0 100% 0
18-24 13 0 2 0 1.0 100% 0
24-36 11 1 1 1 0.90 100% 0
36-48 7 0 3 0 1.0 90% 10.8%
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